Dividendos de Spectral Medical

Dividendo controles de criterios 0/6

Spectral Medical no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.8%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-CA$0.056
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de EDT han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de EDT han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Spectral Medical vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de EDT con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (EDT)	n/a
Suelo de mercado 25% (CA)	1.9%
Techo de mercado 25% (CA)	6.4%
Media de la industria (Biotechs)	2.8%
Previsión de analistas en 3 años (EDT)	n/a

Dividendo destacado: Unable to evaluate EDT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Alto dividendo: Unable to evaluate EDT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de EDT para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que EDT no ha comunicado ningún pago.

Dividendos de Spectral Medical

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Spectral Medical Provides Tigris Trial Update

Less than half of directors are independent

Price target increased by 13% to CA$1.80

Spectral Medical Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Market cap size

Spectral Medical Inc. Provides Update on the Company's Tigris Trial

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Spectral Medical Inc. Provides Early February Tigris Trial Update

Spectral Medical Provides January Tigris Trial Update

Spectral Medical Inc. l Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

Spectral Medical Inc. Provides November Tigris Trial Update

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Publication of Tigris Trial Methods Paper

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Provides Tigris Trial Update

New minor risk - Shareholder dilution

Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding from Paradigm Capital Inc.

Second quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.011 loss in 2Q 2022)

Spectral Medical Inc. Announces Tigris Clinical Trial Update

Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors

Spectral Medical Inc. Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Spectral Medical Inc. Provides Update on Favorable Tigris Clinical Trial Enrollment

Consensus revenue estimates increase by 186%

Consensus revenue estimates decrease by 61%, EPS upgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Inc. Announces Resignation of Jim Funk as Director

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spectral Medical Inc. Provides Update on Tigris Clinical Trial

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CA$2.10

Forecast to breakeven in 2024

Spectral Medical Inc. announced that it has received CAD 6.8364 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Spectral Medical Provides Update on Tigris Clinical Trial

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ for the Treatment of Endotoxemic Septic Shock

Spectral Medical Inc. Elects James Funk as Director

Spectral Medical Inc. Appoints Sam Amory as Dialco, President

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to CA$2.10

Forecast breakeven date pushed back to 2024

Consensus revenue estimates fall by 44%

Spectral Medical Inc., Annual General Meeting, Jun 09, 2022

Spectral Medical Inc. Through Its Wholly-Owned Subsidiary Dialco Medical Inc. Provides Clinical Trial Update on Tigris, A Follow on Study Designed to Build on Knowledge Gained from the Earlier Euphrates Trial

We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate

Forecast to breakeven in 2023

Third quarter 2021 earnings released: CA$0.008 loss per share (vs CA$0.007 loss in 3Q 2020)

Price target decreased to CA$2.85

Independent Chairman of the Board recently bought CA$180k worth of stock

Independent Director Kevin Giese has left the company

Forecast breakeven moved forward to 2022

First quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.015 loss in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: CA$0.039 loss per share (vs CA$0.022 loss in FY 2019)

Spectral Medical Inc.'s (TSE:EDT) Path To Profitability

Spectral Medical Inc., Annual General Meeting, Jun 03, 2021

Independent Director exercised options to buy CA$104k worth of stock.

Spectral Medical Inc. Announces Chief Executive Officer Changes, Effective April 1, 2021

Spectral Medical Inc Crescendo Communications to Provide Investor Relations Services in the United States

Spectral Medical Announces That Its Wholly-Owned Subsidiary Dialco Medical Has Been Granted FDA IDE Authorization to Conduct Trial of Dimi for Home Hemodialysis Use

Spectral Medical (TSE:EDT) Is In A Good Position To Deliver On Growth Plans

New 90-day high: CA$0.69

Spectral Medical Inc Appoints John Kellum as Chief Medical Officer Effective March 1, 2021

New 90-day high: CA$0.54

Spectral Medical's(TSE:EDT) Share Price Is Down 49% Over The Past Five Years.

Spectral Medical Inc. (TSE:EDT): Is Breakeven Near?

Spectral Medical Inc. Announces its Wholly Owned Subsidiary Dialco Medical Receives Mdsap Certification